I n a genomewide differential gene expression study of the mouse cornea, lens, and tendon, we identified the expression of a gene, Pglyrp1, encoding a novel antimicrobial protein, PGLYRP1, in the cornea. 1 Here we further investigated this antimicrobial protein in the cornea. The peptidoglycan recognition proteins (PGRPs) are a large family of pathogenassociated pattern recognition molecules in insects, mollusks, echinoderm, and vertebrates. 2, 3 Mammalian PGRPs, a family of four distinctive homologous gene products, were identified recently. These were originally named peptidoglycan recognition protein-short (PgrpS), peptidoglycan recognition proteinlong (PgrpL), peptidoglycan recognition protein-intermediate alpha and beta (Pgrp I␣ and Pgrp I␤). These have been now renamed Pglyrp1, Pglyrp2, Pglyrp3, and Pglyrp4 in the mouse, based on the names given to the corresponding human homologues by the HUGO Gene Nomenclature Committee. 4, 5 Accordingly, peptidoglycan recognition protein short (PGRPS), the subject of the present study, will be referred to as PGLYRP1, and the mouse gene will be referred to as Pglyrp1. The PGLYRP1 protein has a restricted distribution in the bone marrow and tertiary granules of mature neutrophils. 4 PGLYRP2, a widely expressed, secreted membrane protein, is present in the liver, serum, colon, lymph nodes, heart, thymus, and pancreas. PGLYRP3 and PGLYRP4 are also widely expressed in the esophagus, thymus, skin, and other mucous membranes. 6 PGLYRP2 is a Zn 2ϩ -dependent amidase, hydrolyzes peptidoglycans from bacterial cell walls, and may be important in reducing levels of proinflammatory peptidoglycans to dampen overstimulation of the immune system. 6 PGLYRP1, PGLYRP3, and PGLYRP4 interact with bacterial peptidoglycans, interfere with the biosynthesis of peptidoglycans, and are bactericidal or prevent further growth of bacteria. 6 The concept that peptidoglycan recognition proteins have a role at the ocular surface is very new.
The cornea is the outermost barrier tissue of the eye that is often under attack by fungal, bacterial, and viral pathogens. 7, 8 Tear film-and membrane-associated mucins provide the first barrier to microorganisms. 9 Stratified epithelium and shedding of the surface cells provide a second level of protection for the corneal surface. 10 The cornea has an active innate immune signaling mechanism through the toll-like receptors (TLR). 11, 12 Even lumican, a resident stromal structural protein, contributes to TLR-mediated innate immune response of the cornea. 13 Another major defense mechanism at the ocular surface involves antimicrobial proteins and peptides. Antimicrobial peptides identified in the cornea thus far include the defensins, 14 antifungal histatins, 8 and cathelicidin. 15 Several chemokines in the cornea, such as, MIP-3␣ and thymosin ␤4, have antimicrobial properties in vitro and in vivo. 8 Of the PGLYRP family of antimicrobial proteins, there has been only one report of PGLYRP2 expressed at low levels in the corneal epithelium and upregulated in corneal epithelial cell cultures after exposure to bacteria. 16 In the present study, we show that Pglyrp1 is constitutively expressed in mouse corneal epithelial cells. At the protein level, it is detectable in the mouse and human corneal epithelium. To date this particular member, PGLYRP1, has been detected in bone marrow and circulating neutrophils. 4 Our finding of PGLYRP1 in the corneal epithelium suggests a novel role for this protein in the cornea, implicating another level of antimicrobial defense at the ocular surface. With the use of mice deficient in the Pglyrp1 gene, we investigated how PGLYRP1 functions in the cornea and how its deficiency affects the cornea.
MATERIALS AND METHODS

Animals
BALB/c and Pglyrp1
Ϫ/Ϫ mice 4 backcrossed to the BALB/c background for eight generations (provided by Roman Dziarski) were housed in a specific pathogen-free facility according to policies approved by the Animal Care Committee of Johns Hopkins University. All experiments using mice were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Immunoblotting
The corneal epithelium was separated as a sheet after intact corneas were incubated in 250 L of 20 mM EDTA (sterile, pH 7.4) for 30 minutes at 37°C. Total protein extracts in reagent (T-PER; Pierce Biotechnology, Rockford, IL) were prepared from whole corneas and the isolated corneal epithelium. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose membranes with a transblot apparatus (Bio-Rad, Hercules, CA) at 100 V for 1 hour at 4°C. Nonspecific binding sites were blocked overnight with 3% gelatin (Sigma, St. Louis, MO) in Tris-buffered saline containing 0.1% Tween-20. Immunoblots were incubated with an anti-mouse PGLYRP1 antibody (AF 2696; R&D Systems, Inc., Minneapolis, MN) at a final dilution of 1:500. Membranes were washed and incubated with peroxidase-conjugated donkey antigoat IgG (sc-2020; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Protein bands were detected with the enhanced chemiluminescence kit (GE Healthcare, Chalfont, St. Giles, UK). To confirm equal loading, actin was immunostained with an anti-actin polyclonal antibody (1: 2000; sc-1615; Santa Cruz Biotechnology, Inc.).
Quantitative Real-Time PCR
Total RNA was extracted from isolated corneal epithelial sheets in 1 mL reagent (TRIzol; Invitrogen Corp., Carlsbad, CA). 17 First-strand cDNA was synthesized from 1 g total RNA with a reverse transcriptase enzyme (Superscript II; Invitrogen Corp.) and oligo (dT) primers. Resultant cDNA samples were stored at Ϫ20°C until use. Quantitative real-time PCR (qRT-PCR) was carried out with a sequence detection system (ABI PRISM 7900HT; Applied Biosystems, Foster City, CA) and PCR master mix (SYBR Green; Applied Biosystems). Reaction conditions were 50°C for 2 minutes, 95°C for 10 minutes, and 45 cycles of 95°C for 15 seconds and 59°C and 72°C for 30 seconds each. Specificity of the PCR products was confirmed by examination of the dissociation curves of the products. Primers used were as follows: Gapdh, (forward) 5Ј-CCCTGGCCAAGGTCATCC-3Ј, (reverse) 5Ј-TGAT-GGCATGGACTGTGGTC-3Ј; Pglyrp1, (forward) 5Ј-GCAATGTGCAG-CATTACCAC-3Ј, (reverse) 5Ј-CTGTGTGGTCACCCTTGATG-3Ј. A threshold cycle number (C T ) was determined using the ABI-SDS software, and a mean C T value was obtained from triplicate reactions. The threshold cycle difference was calculated as follows: ⌬C T ϭ (C T of Pglyrp1 Ϫ C T of Gapdh), and relative expression was defined as 2 Ϫ⌬CT .
Confocal Microscopy
Whole mouse eyes were frozen in OCT (Tissue-Tek; Sakura Finetek, Zoeterwoude, Netherlands), and 20-m-thick sections were prepared. 18 Cryosections of the human cornea were kindly provided by Albert Jun (Johns Hopkins University). Mouse and human cornea cryosections were methanol-fixed and blocked with 2% BSA in PBS containing 0.2% nonionic surfactant (Triton X100; Sigma) for 30 minutes at room temperature. The sections were washed thoroughly and incubated with primary antibodies against PGLYRP1 (mouse, AF 2696 [R&D Systems, Inc.] at 1:500 dilution; human, sc-55745 [Santa Cruz Biotechnology Inc.] at 1:100 dilution) at room temperature. A fluorescence-labeled secondary antibody (A-21446, Alexa Fluor 647 anti-goat IgG; Molecular Probes, Eugene, OR) was used at a 1:400 dilution for 30 minutes at room temperature. The sections were counterstained with 4Ј,6Ј-diamidin-2-phenylindole (DAPI; 1 g/mL). Negative controls consisted of sections treated as described but without the primary antibody. Imaging was performed under a single-photon microscope (LSM 510 Meta Confocal; Zeiss) using 20ϫ, 40ϫ or 100ϫ oil immersion objectives.
Bacteriostatic Activity Assay
To test for bacteriostatic activity, corneal epithelial extracts from Pglyrp1 ϩ/ϩ and Pglyrp1 Ϫ/Ϫ mice were incubated at 37°C for 0, 60, and 120 minutes, with an early log-phase culture of Escherichia coli DH 5␣ in 96-well plates containing 1% LB broth in PBS. A maximum of 5 g protein was used per well, maintaining a ratio of approximately 50 cfu/g corneal epithelial extract. Anti-PGLYRP1 antibody, 1:40 dilution, was included with a set of Pglyrp1 ϩ/ϩ corneal extracts to test whether blocking its target, PGLYRP1, would reduce bacteriostatic activity of the wild-type extract. All conditions were tested in triplicate wells, and the data were presented as the average number of bacterial cfu/well Ϯ SEM.
Pseudomonas aeruginosa Corneal Infection
Pglyrp1 ϩ/ϩ and Pglyrp1 Ϫ/Ϫ mice were infected with Pseudomonas aeruginosa as described. 19 The mice were anesthetized by intraperitoneal injection (0.014 mL/g body weight) of 12.5 mg/mL tribromoethanol. One cornea per animal (n ϭ 4) was scarified with a 26-gauge needle, and 4.5 ϫ 10 5 cfu bacteria in 2.5 L Dulbecco modified Eagle medium was introduced to the cornea. The eyes were examined under a dissecting microscope (SMZ 1500; Nikon, Tokyo, Japan) fitted with a fluorescein/FITC filter. The images were captured with a digital camera (DXM 1200; Nikon) at 0, 6, and 24 hours and 7 days after infection. In a second similar experiment, we used six mice per group. One cornea per animal was scarified, and 8 ϫ 10 5 cfu bacteria were applied. Corneas were harvested 5 days after infection and homogenized, and up to three different dilutions were plated in nutrient agar plates, in triplicate, to obtain total bacterial counts.
Corneal Wounding
The mice were anesthetized, and one eye was treated topically with proparacaine hydrochloride 0.5% (Bausch and Lomb Pharmaceuticals, Inc., Tampa, FL) before wounding; the other eye was left uninjured. To study wound healing, circular wounds were made with an Alger brush II (0.5 mm; Katena Products, Inc., Denville, NJ) as described. 20 With the use of a Hamilton syringe, wounded corneas were inoculated with 1 L (10 g/L) Staphylococcus aureus peptidoglycans (Sigma). Fluorescein sodium benoxinate hydrochloride ophthalmic solution (Bausch and Lomb Pharmaceuticals, Inc.) was used to visualize the wound margins. At 0 and 24 hours after wounding, the eyes were photographed as described. Captured images were analyzed with image analysis software (NIS-Elements AR 3.0; Nikon). Residual wound, expressed as a percentage of the original wound area, was taken as a measure of the extent of healing.
RESULTS
Presence of PGLYRP-1 at High Levels in the Cornea
Our earlier microarray gene expression study indicated strong expression of Pglyrp1 in the mouse cornea. 1 Here we tested whether Pglyrp1 is expressed in the mouse corneal epithelium by qRT-PCR. Pglyrp1 mRNA, compared with Gapdh, was measured in total RNA extracts of the corneal epithelium from wild-type mice. The results indicated strong expression of Pglyrp1 in the epithelium, with relative expression approximately twofold higher than that of the housekeeping Gapdh gene (Table 1) .
We next sought to determine the presence of the PGLYRP1 protein in the mouse cornea by immunoblotting. A single PGLYRP1 band of the expected size (approximately 16 kDa) was seen in protein extracts of the whole cornea (Fig. 1A) . Total protein extract from the bone marrow, used as a positive control, yielded a PGLYRP1 protein band of the same size. The PGLYRP1-deficient mouse (Pglyrp1 Ϫ/Ϫ ) bone marrow and corneal extracts were negative for PGLYRP1, as expected.
In previous studies, the PGLYRP1 protein had been detected in the bone marrow and circulating neutrophils only; therefore, we wanted to further confirm our finding of PGLYRP1 in the cornea. RT-PCR results indicated Pglyrp1 transcript expression in the corneal epithelium. We next sought to determine the presence of PGLYRP1 in corneal
epithelium by immunoblotting total protein extracted from the isolated epithelium (Fig. 1B) . Taken together, these experiments suggest constitutive high expression of Pglyrp1 in the corneal epithelium.
To further localize PGLYRP1 within the corneal epithelium, frozen sections of the cornea from wild-type (Pglyrp1 ϩ/ϩ ) and Pglyrp1 Ϫ/Ϫ mice were immunostained with an anti-PGLYRP1 antibody, and the sections were viewed by confocal microscopy. PGLYRP1 was clearly visible in the differentiated superficial and the upper wing cells of the epithelium from Pglyrp1 ϩ/ϩ mouse corneas. Furthermore, it was not detectable in the basal undifferentiated cell layer of the cornea. As expected, the Pglyrp1 Ϫ/Ϫ mouse corneas were negative for PG-LYRP1 immunostaining (Fig. 2) . Frozen sections of human cornea were immunostained to test for the presence of PG-LYRP1. As in the mouse, PGLYRP1 was detected primarily in the superficial layers of the epithelium (Figs. 3B, D, J, L) . The results also indicated that stroma in the mouse and human corneas were negative for PGLYRP1 (Figs. 2B, 3B ).
Reduced Antimicrobial Properties of Corneal Epithelial Protein Extracts from Pglyrp1
؊/؊ Mice Bovine PGLYRP1 purified from granulocyte extracts has bacteriostatic and bactericidal properties. 21 We sought to determine whether corneal epithelial PGLYRP1 has antibacterial properties. Corneal epithelial protein extracts from wild-type and Pglyrp1 null mice were incubated with E. coli DH5␣ cultures in early log phase in 96-well plates. Bacterial colony-forming units were calculated at 60 and 120 minutes after inoculation (Fig. 4) . The number of bacteria had almost doubled in the control wells not treated with epithelial protein extracts. In contrast, those treated with epithelial extracts from Pglyrp1 ϩ/ϩ mice showed no increase in the number of bacterial colony-forming units after 1 or 2 hours of incubation. Thus, the Pglyrp1 ϩ/ϩ corneal epithelial extract prevented bacterial growth. Moreover, this activity was lost on pretreatment of the extract with an anti-PGLYRP1 antibody. The Pglyrp1 Ϫ/Ϫ epithelial extract, on the other hand, showed little to no bacteriostatic activity. The results indicate that PGLYRP1 in the corneal epithelium has bacterial growth-deterrent activity.
Poor Healing of Pseudomonas aeruginosa Corneal Infection in Pglyrp1
؊/؊ Mice Given that P. aeruginosa is a common cause of bacterial infections of the cornea, we sought to determine whether Pglyrp1 has a role in protecting the cornea against this bacterium. We used a mouse model of corneal scarification 19 to compare P. aeruginosa infections of the cornea in Pglyrp1
and Pglyrp1 ϩ/ϩ mice. Examination of the infected corneas showed considerable healing in the wild-type mice by 24 hours and completely healed corneas by 7 days (Fig. 5A) . In contrast, the Pglyrp1 Ϫ/Ϫ mice began to show exacerbated signs of infection by 24 hours. To obtain a quantitative estimate of bacterial yield from infected corneas, wild-type and Pglyrp1 Ϫ/Ϫ mice (n ϭ 6 per group) were challenged with P. aeruginosa. The mice were humanely killed after 5 days, and the corneas were homogenized to obtain total bacterial yield. Because the distributions of bacterial counts were highly skewed toward large values and control and knockout mice had substantially different scales, we used the nonparametric Wilcoxon rank sum test to test for a difference in means. The two-sided test was highly significant and gave a P value of 0.00866). Alternatively, a two-sided, two-sample t-test of the log-transformed data (in this case, one control sample with no bacterial counts was taken as 1 cfu) gave a P value of 0.006556 (Fig. 5B) . Thus, there was a significantly higher yield of bacteria from corneal infections of Pglyrp1 Ϫ/Ϫ mice, indicating a compromise in their ability to fight P. aeruginosa corneal infections.
Delayed Healing of Corneal Wounds in
Pglyrp1-Deficient Mice
The Pglyrp gene family is known to regulate host innate immune response and tissue homeostasis in insects. 22 Little is known about whether mammalian Pglyrp1 has a similar role in host innate immune response and cell survival signals. To address this question, we investigated the healing of noninfectious corneal epithelial wounds in Pglyrp1 Ϫ/Ϫ and Pglyrp1 ϩ/ϩ mice. Circular corneal wounds were created using an Alger brush, as described, 20 and S. aureus peptidoglycan was added to the wounds. Observed under a fluorescence dissecting microscope, the Pglyrp1 ϩ/ϩ showed almost complete healing while remaining wounds were visible in the Pglyrp1 Ϫ/Ϫ mice (Fig. 6A) . In the Pglyrp1 Ϫ/Ϫ mice, 17% to 29% of the original wound areas remained after 24 hours, as opposed to only 0% to 12% in the wild types (Fig. 6B) .
DISCUSSION
Our earlier genomewide gene expression study identified high transcript levels of a novel antimicrobial protein, Pglyrp1, in the mouse cornea. 1 As a follow-up to this initial observation, here we investigated its expression and role in the mouse cornea using several different approaches. First immunoblotting detected PGLYRP1 in total protein extracts from the mouse cornea. Further immunoblotting of corneal epithelial protein extracts showed the presence of this protein in the showed diffuse fluorescein staining and cloudy patches (arrow) indicative of bacterial infections, whereas the Pglyrp1 ϩ/ϩ cornea appeared healthy. (B) Bacterial yield from homogenized corneas 5 days after scarification and bacterial inoculation. Data points are mean of three measurements from each animal (n ϭ 6 per genotype). P ϭ 0.00866 (Wilcoxon rank sum test) or P ϭ 0.006556 (two-sided, two-sample ttest of the log-transformed data, where one wild-type mouse with 0 cfu was taken as 1 cfu).
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epithelium. By immunohistochemistry, we detected PGLYRP1 in the epithelial wing and superficial cells, with no detectable immunostaining of the basal undifferentiated epithelial layer.
Immunostaining of sections of the human cornea also indicated its presence in the superficial epithelial layers. To our knowledge, this is the first report of the PGLYRP1 antimicrobial protein at the ocular surface. There is only one other report of another member of this family, PGLYRP2 at the ocular surface. That study reported low levels of PGLYRP2 transcript in the cornea, and the Pglyrp2 gene was inducible to low levels in a human corneal epithelial cell line in the presence of bacteria. 16 Microbe-host interactions are beginning to be recognized as playing a directive role in maintaining an optimally active innate immune response and epithelial homoeostasis in the host. 23 Similar microbial influence underpinning corneal epithelial homeostasis and regulation of Pglyrp1 expression in the cornea by microbe-host interactions are unknown. Our results show constitutive high expression of PGLYRP1 in the mouse cornea, both at the mRNA and at the protein level. However, the present study and all previous reports on Pglyrp1 have used mice raised in specific pathogenfree (SPF) facilities. The mucosal surfaces of SPF mice are colonized with commensal and some pathogenic bacteria. It is not known whether Pglyrp1 is expressed equally well in mice, raised in germ-free facilities, free of all aerobic and anaerobic microbes.
Another point of speculation is how PGLYRP1 is stored or secreted by the epithelium. Epithelial secretion of antimicrobial proteins/peptides has been studied extensively in the gut. For example, intestinal Paneth cells make, and store large amounts of ␣ defensins, which are released in the crypt in response to specific signals. 24, 25 PGLYRP3 and PGLYRP4 are expressed in the intestinal columnar absorptive epithelial cells, not Paneth cells, and increase in response to bacterial exposure. 6 In the stratified corneal epithelium, the release of antimicrobial proteins/peptides may be different. PGLYRP1 may simply be released during natural sloughing off of the surface epithelial cells and their breakdown. On the other hand, PGLYRP1 has a signal peptide and may be secreted by surface epithelial cells in a regulated manner. At least in neutrophils it is known to be stored in tertiary granules. In activated neutrophils, it colocalizes with lysozyme in neutrophil extracellular traps and has a synergistic antibacterial effect with lysozyme. 26 To date, mammalian Pglyrp1 has been associated with antibacterial functions only. In contrast, the insect Pglyrp1 ortholog is known to be antibacterial and to cross-talk with Toll and other innate immune and survival signal-regulating genes. We found a small, but significant, delay in the healing of noninfectious corneal epithelial wounds in Pglyrp1 Ϫ/Ϫ mice. The epithelium initiates rapid healing of corneal wounds by downregulating apoptosis and promoting cell proliferation, growth, and migration. 27 Delayed healing of epithelial wounds in Pglyrp1 Ϫ/Ϫ mice suggests a role for PGLYRP1 in modulating these epithelial cell survival and homeostatic signals. In addition, our study shows that, like the neutrophil-PGLYRP1, the corneal protein is also antibacterial. The wild type, but not the Pglyrp1 Ϫ/Ϫ , corneal epithelial protein extract prevented bacterial growth in culture. Bacteriostatic activity was lost on incubation of the Pglyrp1 ϩ/ϩ corneal extract with anti-PGLYRP1 antibody; confirming the bacteriostatic activity to be specifically caused by PGLYRP1. P. aeruginosa is a common cause of cornea infections in humans. 28 In our study, Pglyrp1
Ϫ/Ϫ mice showed exacerbated P. aeruginosa corneal infections and a failure to clear the bacteria, indicating a role for PG-LYRP1 in antibacterial defense against this bacterium. PG-LYRP1 may also have a role in epithelial wound healing signals, and this could secondarily affect healing of infectious wounds. An earlier study reported reduced survival of Pglyrp1 Ϫ/Ϫ mice challenged systemically with the Gram-positive bacterium Bacillus subtilis. 4 Recombinant mammalian PGLYRP1 binds lysine-type Gram-positive and meso-diaminopimelic acid type Gram-negative bacterial peptidoglycans. 26 It can also recognize bacterial lipopolysaccharides and possibly pathogen-associated molecular patterns of fungal origin, suggesting a broad antimicrobial property. 21, 29 Additional studies of PGLYRP1 are needed to elucidate its role in the cornea and to identify pathogen targets. Indeed, constitutively high levels of PGLYRP1 in the corneal epithelium may mean that this antimicrobial protein is a broadspectrum resident pathogen deterrent at the ocular surface. 
